Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

Xiangyu Yan, Songhan Huang, Yang Yang, Ziwen Lu, Feiyu Li, Liyong Jiang, Yong Jiang, Jun Liu – 15 December 2021 – The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVL]) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research. Therefore, we performed this systematic review and meta‐analysis to investigate the potential survival benefits of mTOR inhibitors (mTORis).

Adverse Effects of Anti‐Covid‐19 Drug Candidates and Alcohol on Cellular Stress Responses of Hepatocytes

Atousa Khalatbari, Zahra Aghazadeh, Cheng Ji – 14 December 2021 – During the pandemic, dexamethasone (DEX), remdesivir (RDV), hydroxychloroquine (HCQ), thapsigargin (TG), camostat mesylate (CaM), and pralatrexate were repurposed drugs for coronavirus disease 2019 (COVID‐19). However, the side effects on the liver associated with the anti‐COVID therapies are unknown. Cellular stresses by these drugs at 0‐30 μM were studied using HepG2, Huh7, and/or primary human hepatocytes.

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis

Thomas Reiberger – 13 December 2021 – Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents.

Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B

Hannah S.J. Choi, Alexander Tonthat, Harry L.A. Janssen, Norah A. Terrault – 9 December 2021 – Chronic hepatitis B virus (HBV) infection remains difficult to cure due to the persistent, self‐replenishing nature of the viral genome and impaired host immune responses. Current treatment goals for chronic hepatitis B (CHB) are to prevent or significantly delay liver‐related adverse outcomes and death, and two types of treatments are available: nucleos(t)ide analogues (NAs) and interferons (IFNs).

Subscribe to